SI2376121T2 - Zdravljenje osteoartritisa - Google Patents

Zdravljenje osteoartritisa

Info

Publication number
SI2376121T2
SI2376121T2 SI200931446T SI200931446T SI2376121T2 SI 2376121 T2 SI2376121 T2 SI 2376121T2 SI 200931446 T SI200931446 T SI 200931446T SI 200931446 T SI200931446 T SI 200931446T SI 2376121 T2 SI2376121 T2 SI 2376121T2
Authority
SI
Slovenia
Prior art keywords
osteoarthritis treatment
osteoarthritis
treatment
Prior art date
Application number
SI200931446T
Other languages
English (en)
Slovenian (sl)
Inventor
John Allan Hamilton
Andrew David Cook
Original Assignee
The University Of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42286786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2376121(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The University Of Melbourne filed Critical The University Of Melbourne
Publication of SI2376121T2 publication Critical patent/SI2376121T2/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Virology (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Polarising Elements (AREA)
  • Glass Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SI200931446T 2008-12-22 2009-12-21 Zdravljenje osteoartritisa SI2376121T2 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13967908P 2008-12-22 2008-12-22
US16448609P 2009-03-30 2009-03-30
EP09833924.5A EP2376121B2 (en) 2008-12-22 2009-12-21 Osteoarthritis treatment
PCT/AU2009/001672 WO2010071924A1 (en) 2008-12-22 2009-12-21 Osteoarthritis treatment

Publications (1)

Publication Number Publication Date
SI2376121T2 true SI2376121T2 (sl) 2021-11-30

Family

ID=42286786

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200931446T SI2376121T2 (sl) 2008-12-22 2009-12-21 Zdravljenje osteoartritisa
SI200931446A SI2376121T1 (sl) 2008-12-22 2009-12-21 Zdravljenje osteoartritisa

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200931446A SI2376121T1 (sl) 2008-12-22 2009-12-21 Zdravljenje osteoartritisa

Country Status (19)

Country Link
US (4) US9243061B2 (OSRAM)
EP (2) EP2376121B2 (OSRAM)
JP (3) JP5727379B2 (OSRAM)
KR (2) KR101898982B1 (OSRAM)
CN (2) CN106397591A (OSRAM)
AU (1) AU2009329814B2 (OSRAM)
BR (1) BRPI0918356B1 (OSRAM)
CA (1) CA2746827C (OSRAM)
CY (1) CY1117698T1 (OSRAM)
DK (1) DK2376121T4 (OSRAM)
ES (2) ES2572368T5 (OSRAM)
HK (1) HK1226938A1 (OSRAM)
HR (1) HRP20160577T4 (OSRAM)
HU (1) HUE028615T2 (OSRAM)
PL (1) PL2376121T5 (OSRAM)
RU (2) RU2011127334A (OSRAM)
SI (2) SI2376121T2 (OSRAM)
SM (1) SMT201600156B (OSRAM)
WO (1) WO2010071924A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2978209T3 (es) 2008-12-22 2024-09-09 Univ Melbourne Tratamiento del dolor
US9243061B2 (en) * 2008-12-22 2016-01-26 University Of Melbourne Osteoarthritis treatment
CN109999195A (zh) 2012-09-20 2019-07-12 莫弗系统股份公司 类风湿关节炎的治疗
DE102013222200A1 (de) * 2013-10-31 2015-08-27 Osram Opto Semiconductors Gmbh Elektronisches Bauelement und Verfahren zum Herstellen eines elektronischen Bauelements
IL301622A (en) * 2017-08-14 2023-05-01 Zynerba Pharmaceuticals Inc Methods for treating degenerative joint disease with cannabidiol gel through the skin
WO2020104833A1 (en) * 2018-11-19 2020-05-28 4P-Pharma Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
CA2062975A1 (en) 1989-07-14 1991-01-15 Gail F. Seelig Antagonists of gm-csf derived from the carboxyl terminus
DE69031914T2 (de) 1989-08-11 1998-07-30 Amrad Corp. Ltd., Kew, Victoria Rezeptor für granulozyten-macrophagen-koloniestimulierungsfaktor und seine derivate
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
CA2149881A1 (en) 1992-11-19 1994-05-26 Paul T. Jubinsky Antibodies for gm-csf receptor and uses thereof
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US20060067938A1 (en) * 2001-10-26 2006-03-30 Sherif Daouti Methods for the treatment of osteoarthritis and compositions thereof
ATE444308T1 (de) 2002-02-13 2009-10-15 Ludwig Inst Cancer Res Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
US20040241755A1 (en) * 2003-06-02 2004-12-02 Pfizer Inc. Human cell assay to determine effect of sample compounds on Col2 enhancer expression
JP2008505054A (ja) 2004-02-11 2008-02-21 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｉｌ−６アンタゴニストで骨関節炎を治療する方法
JP4825667B2 (ja) * 2004-03-31 2011-11-30 一和 中尾 関節炎症治療剤又は予防剤
EP1593690B1 (en) 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
US7662573B2 (en) * 2004-08-18 2010-02-16 The United States Of America As Represented By The Department Of Health And Human Services Methods for evaluating osteoarthritis risk
US20060040258A1 (en) 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
EA013162B1 (ru) 2005-04-18 2010-02-26 Микромет Аг Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
BRPI0610796B8 (pt) 2005-05-18 2021-05-25 Morphosys Ag anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CA2629850A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
CN101501070B (zh) 2006-02-08 2013-12-25 诺福泰克公司 抗原性gm-csf肽和针对gm-csf的抗体
CN103641916A (zh) 2006-03-27 2014-03-19 医学免疫有限公司 Gm-csf受体结合元件
US7741273B2 (en) * 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
NZ598345A (en) * 2006-11-21 2013-09-27 Kalobios Pharmaceuticals Inc Methods of treating chronic inflammatory diseases using a gm-csf antagonist
WO2008080134A2 (en) * 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
CN101687926A (zh) * 2007-05-23 2010-03-31 哮喘和气道Crc有限公司 中和抗体
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US20090163440A1 (en) * 2007-09-26 2009-06-25 Waddell David D Ion-Channel Regulator Compositions and Methods of Using Same
EP2217626A4 (en) 2007-11-12 2011-06-22 Crc For Asthma And Airways Ltd EPITOP FOR NEUTRALIZING ANTIBODIES
TWI434854B (zh) 2007-11-13 2014-04-21 Evec Inc 結合ｈＧＭ－ＣＳＦ的單株抗體以及包含其之醫學組成物
WO2009118662A2 (en) 2008-03-24 2009-10-01 Abbott Biotechnology Ltd. Methods and compositions for treating bone loss
JP5688363B2 (ja) * 2008-04-28 2015-03-25 カロバイオス ファーマシューティカルズ インコーポレイティッド 顆粒球−マクロファージコロニー刺激因子に対する抗体
US9243061B2 (en) 2008-12-22 2016-01-26 University Of Melbourne Osteoarthritis treatment
ES2978209T3 (es) 2008-12-22 2024-09-09 Univ Melbourne Tratamiento del dolor
SG175305A1 (en) 2009-04-23 2011-11-28 Theraclone Sciences Inc Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies

Also Published As

Publication number Publication date
PL2376121T3 (pl) 2016-12-30
EP3056217A1 (en) 2016-08-17
WO2010071924A1 (en) 2010-07-01
BRPI0918356B1 (pt) 2022-03-08
KR20110128273A (ko) 2011-11-29
AU2009329814A1 (en) 2010-07-01
JP2017200933A (ja) 2017-11-09
ES2572368T5 (es) 2021-12-16
KR20170128630A (ko) 2017-11-22
EP2376121A4 (en) 2013-04-03
HRP20160577T4 (hr) 2021-08-20
RU2016102339A (ru) 2018-11-21
JP6458086B2 (ja) 2019-01-23
PL2376121T5 (pl) 2021-09-27
AU2009329814B2 (en) 2015-06-18
CY1117698T1 (el) 2017-05-17
CN106397591A (zh) 2017-02-15
CA2746827A1 (en) 2010-07-01
RU2712273C2 (ru) 2020-01-28
EP3056217B1 (en) 2021-06-30
JP5727379B2 (ja) 2015-06-03
CA2746827C (en) 2018-01-23
HRP20160577T1 (hr) 2016-07-29
HUE028615T2 (en) 2016-12-28
EP2376121B1 (en) 2016-03-09
DK2376121T3 (en) 2016-05-30
KR101898982B1 (ko) 2018-09-14
DK2376121T4 (da) 2021-08-16
US9243061B2 (en) 2016-01-26
KR101799264B1 (ko) 2017-11-20
JP2015143233A (ja) 2015-08-06
ES2572368T3 (es) 2016-05-31
EP2376121B2 (en) 2021-06-09
US20200247895A1 (en) 2020-08-06
RU2016102339A3 (OSRAM) 2019-07-29
SI2376121T1 (sl) 2016-07-29
HK1226938A1 (en) 2017-10-13
US20180066062A1 (en) 2018-03-08
US20160185868A1 (en) 2016-06-30
JP2012512815A (ja) 2012-06-07
ES2886063T3 (es) 2021-12-16
BRPI0918356A2 (pt) 2020-10-06
RU2011127334A (ru) 2013-01-27
US20120003234A1 (en) 2012-01-05
CN102271705A (zh) 2011-12-07
SMT201600156B (it) 2016-08-31
EP2376121A1 (en) 2011-10-19

Similar Documents

Publication Publication Date Title
IL213619A0 (en) Treatment
GB0802116D0 (en) Treatment
EP2322076A4 (en) ENDOSCOPE OF TREATMENT
GB0806419D0 (en) Process
IL212348A0 (en) Treatment method
GB0822011D0 (en) Treatment
GB0711342D0 (en) Well treatment
GB0817067D0 (en) Intestinal treatment
GB0807850D0 (en) Treatment device
GB0811992D0 (en) Treatment
SI2376121T2 (sl) Zdravljenje osteoartritisa
GB0900599D0 (en) Treatment
GB201013898D0 (en) Well treatment
GB0716784D0 (en) Well treatment
GB0913968D0 (en) Treatment
GB0802201D0 (en) Treatment system
GB0820972D0 (en) Treatment
GB201001521D0 (en) Treatment
PL2263454T3 (pl) Kompozycja uzdatniająca
GB0808357D0 (en) Process
GB0805912D0 (en) Treatment
GB0809046D0 (en) Cancer treatment
GB0823273D0 (en) Treatment system
GB2465211B (en) Treatment Solution
GB0820534D0 (en) Treatment